- Home
- IONR vs IPHA Comparison
IONR vs IPHA Comparison
Compare IONR & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONR
- IPHA
- Stock Information
- Founded
- IONR 2001
- IPHA 1999
- Country
- IONR Australia
- IPHA France
- Employees
- IONR N/A
- IPHA N/A
- Industry
- IONR
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- IONR
- IPHA Health Care
- Exchange
- IONR Nasdaq
- IPHA Nasdaq
- Market Cap
- IONR 319.2M
- IPHA 148.3M
- IPO Year
- IONR N/A
- IPHA 2019
- Fundamental
- Price
- IONR $4.11
- IPHA $1.79
- Analyst Decision
- IONR
- IPHA Strong Buy
- Analyst Count
- IONR 0
- IPHA 1
- Target Price
- IONR N/A
- IPHA $11.50
- AVG Volume (30 Days)
- IONR 25.0K
- IPHA 779.8K
- Earning Date
- IONR 01-01-0001
- IPHA 09-12-2024
- Dividend Yield
- IONR N/A
- IPHA N/A
- EPS Growth
- IONR N/A
- IPHA N/A
- EPS
- IONR N/A
- IPHA N/A
- Revenue
- IONR N/A
- IPHA $36,202,722.00
- Revenue This Year
- IONR N/A
- IPHA N/A
- Revenue Next Year
- IONR N/A
- IPHA $101.65
- P/E Ratio
- IONR N/A
- IPHA N/A
- Revenue Growth
- IONR N/A
- IPHA N/A
- 52 Week Low
- IONR $2.90
- IPHA $1.29
- 52 Week High
- IONR $9.35
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- IONR 42.24
- IPHA 45.92
- Support Level
- IONR $3.71
- IPHA $1.64
- Resistance Level
- IONR $4.58
- IPHA $1.87
- Average True Range (ATR)
- IONR 0.34
- IPHA 0.12
- MACD
- IONR 0.07
- IPHA -0.04
- Stochastic Oscillator
- IONR 51.04
- IPHA 28.66
About IONR ioneer Ltd
Ioneer Ltd is a mineral exploration company. The company's focus is on the Rhyolite Ridge Lithium-Boron Project located in Nevada, USA. Geographically, the group has a business presence in Australia and North America. The company's focus is to develop a U.S.-based source of lithium and boron that can be extracted in an environmentally and socially responsible manner, providing two materials that are essential to achieve a sustainable future for the planet.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.